Selected research
Industry Growth & Trends
Global Cell Therapy CDMO Industry Growth and Trends Forecast to 2032
Market perspective
According to APO Research, the global Cell Therapy CDMO market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.
The North America market for Cell Therapy CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.
The Europe market for Cell Therapy CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.
Read the full market overview
The Asia Pacific market for Cell Therapy CDMO is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.
Leading global companies in the Cell Therapy CDMO market include Catalent, Lonza, Charles River, FUJIFILM Diosynth Biotechnologies, Exothera, Pharmaron, OBiO, AGC Biologics and Cytiva, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report provides a structured, data-driven view of the global Cell Therapy CDMO market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.
The Cell Therapy CDMO market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Cell Therapy CDMO market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Cell Therapy CDMO.
Key Companies & Market Share Insights
This section analyzes the strategies and performance of leading companies in the global Cell Therapy CDMO market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.
Cell Therapy CDMO Market by Company
Catalent
Lonza
Charles River
FUJIFILM Diosynth Biotechnologies
Exothera
Pharmaron
OBiO
AGC Biologics
Cytiva
ThermoGenesis
eXmoor Pharma
Advanced Therapies
Catalent Biologics
Patheon Pharma Services
Sartorius
Genezen
The Discovery Labs
Cell Therapy CDMO Segment by Type
Autologous Cell Therapy CDMO
Allogeneic Cell Therapy CDMO
Viral Vector and Gene Editing CDMO
Cell Therapy CDMO Segment by Application
Commercial
Academic Research
Others
Cell Therapy CDMO Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cell Therapy CDMO market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cell Therapy CDMO and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cell Therapy CDMO.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 5: Detailed analysis of Cell Therapy CDMO companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.
Chapter 12: Concluding Insights of the report
More report detail
Tables and figures
Scope & coverage.
Types
- Autologous Cell Therapy CDMO
- Allogeneic Cell Therapy CDMO
- Viral Vector and Gene Editing CDMO
Applications
- Commercial
- Academic Research
- Others
Companies covered
- Catalent
- Lonza
- Charles River
- FUJIFILM Diosynth Biotechnologies
- Exothera
- Pharmaron
- OBiO
- AGC Biologics
- Cytiva
- ThermoGenesis
- eXmoor Pharma
- Advanced Therapies
- Catalent Biologics
- Patheon Pharma Services
- Sartorius
- Genezen
- The Discovery Labs
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Global Market Growth Prospects
- 1.3 Global Cell Therapy CDMO Market Size Overview by Region 2021 VS 2025 VS 2032
- 1.4 Global Cell Therapy CDMO Market Size by Region (2021-2032)
- 1.4.1 Global Cell Therapy CDMO Market Size by Region (2021-2026)
- 1.4.2 Global Cell Therapy CDMO Market Size by Region (2027-2032)
- 1.5 Key Regions Cell Therapy CDMO Market Size (2021-2032)
- 1.5.1 North America Cell Therapy CDMO Market Size Growth Rate (2021-2032)
- 1.5.2 Europe Cell Therapy CDMO Market Size Growth Rate (2021-2032)
- 1.5.3 Asia-Pacific Cell Therapy CDMO Market Size Growth Rate (2021-2032)
- 1.5.4 South America Cell Therapy CDMO Market Size Growth Rate (2021-2032)
- 1.5.5 Middle East & Africa Cell Therapy CDMO Market Size Growth Rate (2021-2032)
2 Cell Therapy CDMO Market by Type
- 2.1 Type Introduction
- 2.1.1 Autologous Cell Therapy CDMO
- 2.1.2 Allogeneic Cell Therapy CDMO
- 2.1.3 Viral Vector and Gene Editing CDMO
- 2.2 Global Cell Therapy CDMO Market Size by Type
- 2.2.1 Global Cell Therapy CDMO Market Size Overview by Type (2021-2032)
- 2.2.2 Global Cell Therapy CDMO Historic Market Size Review by Type (2021-2026)
- 2.2.3 Global Cell Therapy CDMO Market Size Forecasted by Type (2027-2032)
- 2.3 Global Cell Therapy CDMO Market Size by Regions
- 2.3.1 North America Cell Therapy CDMO Market Size Breakdown by Type (2021-2026)
- 2.3.2 Europe Cell Therapy CDMO Market Size Breakdown by Type (2021-2026)
- 2.3.3 Asia-Pacific Cell Therapy CDMO Market Size Breakdown by Type (2021-2026)
- 2.3.4 South America Cell Therapy CDMO Market Size Breakdown by Type (2021-2026)
- 2.3.5 Middle East and Africa Cell Therapy CDMO Market Size Breakdown by Type (2021-2026)
3 Cell Therapy CDMO Market by Application
- 3.1 Type Introduction
- 3.1.1 Commercial
- 3.1.2 Academic Research
- 3.1.3 Others
- 3.2 Global Cell Therapy CDMO Market Size by Application
- 3.2.1 Global Cell Therapy CDMO Market Size Overview by Application (2021-2032)
- 3.2.2 Global Cell Therapy CDMO Historic Market Size Review by Application (2021-2026)
- 3.2.3 Global Cell Therapy CDMO Market Size Forecasted by Application (2027-2032)
- 3.3 Global Cell Therapy CDMO Market Size by Regions
- 3.3.1 North America Cell Therapy CDMO Market Size Breakdown by Application (2021-2026)
- 3.3.2 Europe Cell Therapy CDMO Market Size Breakdown by Application (2021-2026)
- 3.3.3 Asia-Pacific Cell Therapy CDMO Market Size Breakdown by Application (2021-2026)
- 3.3.4 South America Cell Therapy CDMO Market Size Breakdown by Application (2021-2026)
- 3.3.5 Middle East and Africa Cell Therapy CDMO Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
- 4.1 Cell Therapy CDMO Industry Trends
- 4.2 Cell Therapy CDMO Industry Drivers
- 4.3 Cell Therapy CDMO Industry Opportunities and Challenges
- 4.4 Cell Therapy CDMO Industry Restraints
5 Competitive Insights by Company
- 5.1 Global Top Players by Cell Therapy CDMO Revenue (2021-2026)
- 5.2 Global Cell Therapy CDMO Industry Company Ranking, 2024 VS 2025 VS 2026
- 5.3 Global Cell Therapy CDMO Key Company Headquarters & Area Served
- 5.4 Global Cell Therapy CDMO Company, Product Type & Application
- 5.5 Global Cell Therapy CDMO Company Commercialization Time
- 5.6 Market Competitive Analysis
- 5.6.1 Global Cell Therapy CDMO Market CR5 and HHI
- 5.6.2 Global Top 5 and 10 Cell Therapy CDMO Players Market Share by Revenue in 2025
- 5.6.3 2025 Cell Therapy CDMO Tier 1, Tier 2, and Tier 3
6 Company Profiles
- 6.1 Catalent
- 6.1.1 Catalent Company Information
- 6.1.2 Catalent Business Overview
- 6.1.3 Catalent Cell Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.1.4 Catalent Cell Therapy CDMO Product Portfolio
- 6.1.5 Catalent Recent Developments
- 6.2 Lonza
- 6.2.1 Lonza Company Information
- 6.2.2 Lonza Business Overview
- 6.2.3 Lonza Cell Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.2.4 Lonza Cell Therapy CDMO Product Portfolio
- 6.2.5 Lonza Recent Developments
- 6.3 Charles River
- 6.3.1 Charles River Company Information
- 6.3.2 Charles River Business Overview
- 6.3.3 Charles River Cell Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.3.4 Charles River Cell Therapy CDMO Product Portfolio
- 6.3.5 Charles River Recent Developments
- 6.4 FUJIFILM Diosynth Biotechnologies
- 6.4.1 FUJIFILM Diosynth Biotechnologies Company Information
- 6.4.2 FUJIFILM Diosynth Biotechnologies Business Overview
- 6.4.3 FUJIFILM Diosynth Biotechnologies Cell Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.4.4 FUJIFILM Diosynth Biotechnologies Cell Therapy CDMO Product Portfolio
- 6.4.5 FUJIFILM Diosynth Biotechnologies Recent Developments
- 6.5 Exothera
- 6.5.1 Exothera Company Information
- 6.5.2 Exothera Business Overview
- 6.5.3 Exothera Cell Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.5.4 Exothera Cell Therapy CDMO Product Portfolio
- 6.5.5 Exothera Recent Developments
- 6.6 Pharmaron
- 6.6.1 Pharmaron Company Information
- 6.6.2 Pharmaron Business Overview
- 6.6.3 Pharmaron Cell Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.6.4 Pharmaron Cell Therapy CDMO Product Portfolio
- 6.6.5 Pharmaron Recent Developments
- 6.7 OBiO
- 6.7.1 OBiO Company Information
- 6.7.2 OBiO Business Overview
- 6.7.3 OBiO Cell Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.7.4 OBiO Cell Therapy CDMO Product Portfolio
- 6.7.5 OBiO Recent Developments
- 6.8 AGC Biologics
- 6.8.1 AGC Biologics Company Information
- 6.8.2 AGC Biologics Business Overview
- 6.8.3 AGC Biologics Cell Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.8.4 AGC Biologics Cell Therapy CDMO Product Portfolio
- 6.8.5 AGC Biologics Recent Developments
- 6.9 Cytiva
- 6.9.1 Cytiva Company Information
- 6.9.2 Cytiva Business Overview
- 6.9.3 Cytiva Cell Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.9.4 Cytiva Cell Therapy CDMO Product Portfolio
- 6.9.5 Cytiva Recent Developments
- 6.10 ThermoGenesis
- 6.10.1 ThermoGenesis Company Information
- 6.10.2 ThermoGenesis Business Overview
- 6.10.3 ThermoGenesis Cell Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.10.4 ThermoGenesis Cell Therapy CDMO Product Portfolio
- 6.10.5 ThermoGenesis Recent Developments
- 6.11 eXmoor Pharma
- 6.11.1 eXmoor Pharma Company Information
- 6.11.2 eXmoor Pharma Business Overview
- 6.11.3 eXmoor Pharma Cell Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.11.4 eXmoor Pharma Cell Therapy CDMO Product Portfolio
- 6.11.5 eXmoor Pharma Recent Developments
- 6.12 Advanced Therapies
- 6.12.1 Advanced Therapies Company Information
- 6.12.2 Advanced Therapies Business Overview
- 6.12.3 Advanced Therapies Cell Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.12.4 Advanced Therapies Cell Therapy CDMO Product Portfolio
- 6.12.5 Advanced Therapies Recent Developments
- 6.13 Catalent Biologics
- 6.13.1 Catalent Biologics Company Information
- 6.13.2 Catalent Biologics Business Overview
- 6.13.3 Catalent Biologics Cell Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.13.4 Catalent Biologics Cell Therapy CDMO Product Portfolio
- 6.13.5 Catalent Biologics Recent Developments
- 6.14 Patheon Pharma Services
- 6.14.1 Patheon Pharma Services Company Information
- 6.14.2 Patheon Pharma Services Business Overview
- 6.14.3 Patheon Pharma Services Cell Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.14.4 Patheon Pharma Services Cell Therapy CDMO Product Portfolio
- 6.14.5 Patheon Pharma Services Recent Developments
- 6.15 Sartorius
- 6.15.1 Sartorius Company Information
- 6.15.2 Sartorius Business Overview
- 6.15.3 Sartorius Cell Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.15.4 Sartorius Cell Therapy CDMO Product Portfolio
- 6.15.5 Sartorius Recent Developments
- 6.16 Genezen
- 6.16.1 Genezen Company Information
- 6.16.2 Genezen Business Overview
- 6.16.3 Genezen Cell Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.16.4 Genezen Cell Therapy CDMO Product Portfolio
- 6.16.5 Genezen Recent Developments
- 6.17 The Discovery Labs
- 6.17.1 The Discovery Labs Company Information
- 6.17.2 The Discovery Labs Business Overview
- 6.17.3 The Discovery Labs Cell Therapy CDMO Revenue, Global Share and Gross Margin (2021-2026)
- 6.17.4 The Discovery Labs Cell Therapy CDMO Product Portfolio
- 6.17.5 The Discovery Labs Recent Developments
7 North America
- 7.1 North America Cell Therapy CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 7.2 North America Cell Therapy CDMO Market Size by Country (2021-2026)
- 7.3 North America Cell Therapy CDMO Market Size Forecast by Country (2027-2032)
8 Europe
- 8.1 Europe Cell Therapy CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 8.2 Europe Cell Therapy CDMO Market Size by Country (2021-2026)
- 8.3 Europe Cell Therapy CDMO Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Cell Therapy CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 9.2 Asia-Pacific Cell Therapy CDMO Market Size by Country (2021-2026)
- 9.3 Asia-Pacific Cell Therapy CDMO Market Size Forecast by Country (2027-2032)
10 South America
- 10.1 South America Cell Therapy CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 10.2 South America Cell Therapy CDMO Market Size by Country (2021-2026)
- 10.3 South America Cell Therapy CDMO Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Cell Therapy CDMO Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
- 11.2 Middle East & Africa Cell Therapy CDMO Market Size by Country (2021-2026)
- 11.3 Middle East & Africa Cell Therapy CDMO Market Size Forecast by Country (2027-2032)
12 Concluding Insights
13 Appendix
- 13.1 Reasons for Doing This Study
- 13.2 Research Methodology
- 13.3 Research Process
- 13.4 Authors List of This Report
- 13.5 Data Source
- 13.5.1 Secondary Sources
- 13.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst